Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Pacemakers recalled again | Johnson & Johnson makes a move | GLP-1 drugs & AFib | Strokes after PFA | New LAAO data

News You Need to Know Today
Pacemakers recalled again | Johnson & Johnson makes a move | GLP-1 drugs & AFib | Strokes after PFA | New LAAO data
Monday, May 11, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Editor's Choice: Heart Rhythm

Boston Scientific pacemakers recalled again—software update now available

The new Class I recall, which includes more than 1.4 million devices, is related to an issue first announced back in 2024. Updating the software should address the issue going forward, though some patients may still require an early replacement. 

READ MORE >
FDA recall medical device recall product recall
Share on Twitter Share on Facebook Share on Linkedin

Boston Scientific pacemakers recalled again—software update now available

Share on Twitter Share on Facebook Share on Linkedin
FDA recall medical device recall product recall
The new Class I recall, which includes more than 1.4 million devices, is related to an issue first announced back in 2024. Updating the software should address the issue going forward, though some patients may still require an early replacement. 
READ MORE >

PFA's dominance and other key electrophysiology trends on display at Heart Rhythm 2026

Heart Rhythm 2026 Program Chair DJ Lakkireddy, MD, spoke to Cardiovascular Business during the conference about several key EP trends. 

READ MORE >
Heart Rhythm 2026 Program Chair Dhanunjaya "DJ" Lakkireddy, MD, MBA, FHRS, Executive Medical Director, Kansas City Heart Rhythm Institute, and professor of medicine at the University of Kansas Health System, offers an overview of key trends in electrophysiology (EP) technology.
Share on Twitter Share on Facebook Share on Linkedin

PFA's dominance and other key electrophysiology trends on display at Heart Rhythm 2026

Share on Twitter Share on Facebook Share on Linkedin
Heart Rhythm 2026 Program Chair Dhanunjaya "DJ" Lakkireddy, MD, MBA, FHRS, Executive Medical Director, Kansas City Heart Rhythm Institute, and professor of medicine at the University of Kansas Health System, offers an overview of key trends in electrophysiology (EP) technology.
Heart Rhythm 2026 Program Chair DJ Lakkireddy, MD, spoke to Cardiovascular Business during the conference about several key EP trends. 
READ MORE >

Johnson & Johnson to acquire Atraverse Medical

The move, once finalized, helps Johnson & Johnson add multiple FDA-approved technologies to its EP portfolio.

READ MORE >
healthcare business deal
Share on Twitter Share on Facebook Share on Linkedin

Johnson & Johnson to acquire Atraverse Medical

Share on Twitter Share on Facebook Share on Linkedin
healthcare business deal
The move, once finalized, helps Johnson & Johnson add multiple FDA-approved technologies to its EP portfolio.
READ MORE >

Long-term antidepressant use may increase risk of sudden cardiac death

The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.

READ MORE >
heart drugs with stethoscope
Share on Twitter Share on Facebook Share on Linkedin

Long-term antidepressant use may increase risk of sudden cardiac death

Share on Twitter Share on Facebook Share on Linkedin
heart drugs with stethoscope
The risk appears to be greatest when patients are still actively taking antidepressants. Researchers noted that many more studies on this topic are still necessary.
READ MORE >

Multiple GLP-1 drugs linked to lower AFib risk

The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment. 

READ MORE >
GLP-1 receptor agonists (GLP-1-RAs) have become the wonder drug not only of weight loss, but also for improving cardiovascular health in a growing number of positive cardiovascular trials. The latest study of more than 13,000 patients presented at Heart Rhythm 2026 this week showed the GLP-1 reduce atrial fibrillation (AFib) and survival, even after accounting for the drug’s impact on weight loss.
Share on Twitter Share on Facebook Share on Linkedin

Multiple GLP-1 drugs linked to lower AFib risk

Share on Twitter Share on Facebook Share on Linkedin
GLP-1 receptor agonists (GLP-1-RAs) have become the wonder drug not only of weight loss, but also for improving cardiovascular health in a growing number of positive cardiovascular trials. The latest study of more than 13,000 patients presented at Heart Rhythm 2026 this week showed the GLP-1 reduce atrial fibrillation (AFib) and survival, even after accounting for the drug’s impact on weight loss.
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment. 
READ MORE >

PFA associated with heightened stroke risk

PFA is still quite safe overall. However, new data out of EHRA 2026 suggest cardiologists have much to learn about minimizing risk during treatment. 

READ MORE >
Heart cardiologists doctors surgery
Share on Twitter Share on Facebook Share on Linkedin

PFA associated with heightened stroke risk

Share on Twitter Share on Facebook Share on Linkedin
Heart cardiologists doctors surgery
PFA is still quite safe overall. However, new data out of EHRA 2026 suggest cardiologists have much to learn about minimizing risk during treatment. 
READ MORE >

Cardiologist makes ‘Magic,’ performs first procedure in US with new-look ablation catheter

Users guide the robotically navigated catheter using computer-controlled magnetic fields. It gained FDA approval in January.

READ MORE >
Nathan McConkey, DO, MPH, an electrophysiologist with Oregon Health & Science University (OHSU), made history when he used the Magic Magnetic Interventional Ablation Catheter.
Share on Twitter Share on Facebook Share on Linkedin

Cardiologist makes ‘Magic,’ performs first procedure in US with new-look ablation catheter

Share on Twitter Share on Facebook Share on Linkedin
Nathan McConkey, DO, MPH, an electrophysiologist with Oregon Health & Science University (OHSU), made history when he used the Magic Magnetic Interventional Ablation Catheter.
Users guide the robotically navigated catheter using computer-controlled magnetic fields. It gained FDA approval in January.
READ MORE >

New data point to LAAO as a safe alternative to long-term drug therapy

At the end of the day, one electrophysiologist explained, these decisions should still be made on a case-by-case basis.

READ MORE >
One of the big late-breaking trials presented at the 2026 American College of Cardiology (ACC) Scientific Sessions was the CHAMPION-AF, which showed left atrial appendage occlusion (LAAO) can offer a safe, non-drug alternative to anticoagulation therapy, even in patients with atrial fibrillation who are not at high risk for bleeding. First author of the study Shephal Doshi, MD, FACC, an electrophysiologist at Cedars Sinai Smidt Heart Institute, discussed the details of the trial. #LAAO #ACC #ACC26
Share on Twitter Share on Facebook Share on Linkedin

New data point to LAAO as a safe alternative to long-term drug therapy

Share on Twitter Share on Facebook Share on Linkedin
One of the big late-breaking trials presented at the 2026 American College of Cardiology (ACC) Scientific Sessions was the CHAMPION-AF, which showed left atrial appendage occlusion (LAAO) can offer a safe, non-drug alternative to anticoagulation therapy, even in patients with atrial fibrillation who are not at high risk for bleeding. First author of the study Shephal Doshi, MD, FACC, an electrophysiologist at Cedars Sinai Smidt Heart Institute, discussed the details of the trial. #LAAO #ACC #ACC26
At the end of the day, one electrophysiologist explained, these decisions should still be made on a case-by-case basis.
READ MORE >

FDA approves 2 implantable heart devices from Biotronik

These devices were built to provide better patient data and improve clinician workflows. They will be on display at Heart Rhythm 2026 in Chicago. 

READ MORE >
 The U.S. Food and Drug Administration (FDA) has granted market clearance for Biotronik's Acticor Sky and Rivacor Sky implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The new technology will be launches at the Heart Rhythm Society (HRS) annual meeting this week. #HRS2026
Share on Twitter Share on Facebook Share on Linkedin

FDA approves 2 implantable heart devices from Biotronik

Share on Twitter Share on Facebook Share on Linkedin
 The U.S. Food and Drug Administration (FDA) has granted market clearance for Biotronik's Acticor Sky and Rivacor Sky implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The new technology will be launches at the Heart Rhythm Society (HRS) annual meeting this week. #HRS2026
These devices were built to provide better patient data and improve clinician workflows. They will be on display at Heart Rhythm 2026 in Chicago. 
READ MORE >

FDA approves fast-acting heart drug for children

Landiolol, sold under the brand name Rapiblyk, is only meant to be administered in a hospital setting. It was initially approved for adult patients in 2024.

READ MORE >
pediatric patient young patient child chlidren kid
Share on Twitter Share on Facebook Share on Linkedin

FDA approves fast-acting heart drug for children

Share on Twitter Share on Facebook Share on Linkedin
pediatric patient young patient child chlidren kid
Landiolol, sold under the brand name Rapiblyk, is only meant to be administered in a hospital setting. It was initially approved for adult patients in 2024.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Private equity unlikely to dominate cardiology | Cardiology opposes Medicare AI prior authorization | New AATS leaders
The real impact of RVU cuts in electrophysiology | TAVR changes on the way | Cardiology groups celebrate bill | BP drug recalled
Blood may leak out of Impella introducers | Leadless conduction and Bachmann's pacing | US study for microvascular disease
Top 10 most popular cardiology video interviews this past month
Week in Review: CCTA on ACC expo floor gives cardiologist wake-up call | Reaction to CMS TAVR changes | Recalls and new AI
CCTA scan provides a wake-up call | Resistance training & heart attack risk in women | New ultrasound tech | AFib & grout
FDA clears first surgical valve of its kind | Family files $17M lawsuit | BATMAN to the rescue | Major trends at SCCT 2026

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup